1. Home
  2. LNTH vs NAMS Comparison

LNTH vs NAMS Comparison

Compare LNTH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNTH
  • NAMS
  • Stock Information
  • Founded
  • LNTH 1956
  • NAMS 2019
  • Country
  • LNTH United States
  • NAMS Netherlands
  • Employees
  • LNTH N/A
  • NAMS N/A
  • Industry
  • LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LNTH Health Care
  • NAMS Health Care
  • Exchange
  • LNTH Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • LNTH 3.6B
  • NAMS 3.1B
  • IPO Year
  • LNTH 2015
  • NAMS N/A
  • Fundamental
  • Price
  • LNTH $53.83
  • NAMS $30.67
  • Analyst Decision
  • LNTH Strong Buy
  • NAMS Strong Buy
  • Analyst Count
  • LNTH 6
  • NAMS 10
  • Target Price
  • LNTH $85.50
  • NAMS $41.40
  • AVG Volume (30 Days)
  • LNTH 1.5M
  • NAMS 1.0M
  • Earning Date
  • LNTH 11-05-2025
  • NAMS 11-05-2025
  • Dividend Yield
  • LNTH N/A
  • NAMS N/A
  • EPS Growth
  • LNTH N/A
  • NAMS N/A
  • EPS
  • LNTH 3.77
  • NAMS N/A
  • Revenue
  • LNTH $1,520,653,000.00
  • NAMS $64,006,000.00
  • Revenue This Year
  • LNTH N/A
  • NAMS N/A
  • Revenue Next Year
  • LNTH $3.24
  • NAMS $1.67
  • P/E Ratio
  • LNTH $14.27
  • NAMS N/A
  • Revenue Growth
  • LNTH 5.75
  • NAMS 762.15
  • 52 Week Low
  • LNTH $47.25
  • NAMS $14.06
  • 52 Week High
  • LNTH $118.21
  • NAMS $31.81
  • Technical
  • Relative Strength Index (RSI)
  • LNTH 50.57
  • NAMS 69.35
  • Support Level
  • LNTH $49.75
  • NAMS $27.14
  • Resistance Level
  • LNTH $54.43
  • NAMS $28.91
  • Average True Range (ATR)
  • LNTH 1.51
  • NAMS 1.37
  • MACD
  • LNTH 0.61
  • NAMS 0.40
  • Stochastic Oscillator
  • LNTH 87.11
  • NAMS 86.13

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: